| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02737072 Details | 2019-08-12 Interventional | 1 | 9 | Durvalumab Neoplasms Solid Tumor | - The study was terminated after the Phase 1a part was complete. | |||
| NCT00476996 2006-005330-20 Details | 2019-08-12 Interventional | 3 | 836 | Leflunomide Methotrexate Ocrelizumab Arthritis Arthritis, Rheu… Rheumatoid Arth… | Recruitment was fully completed for this study; however, the study was terminated during
conduct after the primary endpoint analysis was completed. - | |||
| NCT01619566 Details | 2019-08-09 Interventional | 4 | 0 | Duloxetine Hydr… Fibromyalgia Myofascial Pain… | Sponsor related - | |||
| NCT03777579 Details | 2019-08-08 Interventional | 3 | - | Albumin-Bound P… Antibodies Immunoglobulins Paclitaxel Breast Neoplasm… Triple Negative… Triple Negative… | trial handovered to another sponser. - | |||
| NCT03014297 Details | 2019-08-08 Interventional | 1 | 17 | Everolimus Fosbretabulin Neuroendocrine … Everolimus | Part I completed. Part 2 will not be done due to sponsor decision. - | |||
| NCT02983604 2016-002365-63 Details | 2019-08-07 Interventional | 1/2 | 14 | Exemestane Fulvestrant Breast Neoplasm… Advanced Estrog… | - - | |||
| NCT02933814 Details | 2019-08-07 Interventional | 3 | 0 | Bupivacaine Pain | Inadequate number of subjects meet study criteria - | |||
| NCT02634827 Details | 2019-08-07 Interventional | 2 | 1 | Decitabine Midostaurin Staurosporine Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myeloid L… Acute Myeloid L… FLT3 Tyrosine K… Secondary Acute… Untreated Adult… | - - | |||
| NCT01465464 Details | 2019-08-07 Interventional | 3 | 888 | Orantinib Carcinoma Carcinoma, Hepa… Hepatocellular … | - - | |||
| NCT00291408 2005-003297-13 Details | 2019-08-07 Interventional | 4 | 0 | Nitric Oxide Lung Diseases, … Pulmonary Disea… Age Matched Hea… Chronic Obstruc… | Researchers left the institute - | |||
| NCT03429556 Details | 2019-08-05 Interventional | 2 | 23 | Botulinum Toxin… Musculoskeletal… Abdominoplasty | Sponsor decision to terminate early - | |||
| NCT01822496 Details | 2019-08-05 Interventional | 2 | 59 | Albumin-Bound P… Carboplatin Cisplatin Crizotinib Erlotinib Hydro… Etoposide Etoposide phosp… Paclitaxel Podophyllotoxin Tyrosine Kinase… Carcinoma, Non-… Lung Neoplasms Stage III Non-S… Stage IIIA Non-… Stage IIIB Non-… | - This study stopped accrual early due to unmet targeted accrual goals with 59 subjects accrued out of 234 planned. | |||
| NCT00517491 Details | 2019-08-05 Interventional | 2 | 0 | Lanreotide Acromegaly | Administrative reasons - | |||
| NCT03781375 Details | 2019-08-02 Interventional | 3 | 25 | Etanercept Methotrexate Arthritis Arthritis, Juve… Arthritis, Rheu… Juvenile Rheuma… | - - | |||
| NCT00837590 Details | 2019-08-01 Interventional | 1 | 16 | Salicylsalicyli… Sodium Salicyla… Glucose Intoler… Inflammation Obesity Prediabetic Sta… Pre-diabetes | Preliminary results indicated no measurable benefit. This study was a small pilot not powered for main outcomes; the goal was to gather preliminary data for future grants. | |||
| NCT03391050 Details | 2019-07-31 Interventional | 1/2 | 3 | Dabrafenib Melanoma | Target patient population - difficult to find patientes - | |||
| NCT02531633 Details | 2019-07-31 Interventional | 3 | 161 | Antibodies, Mon… Prednisone Arteritis Giant Cell Arte… Polymyalgia Rhe… | GSK decision to return rights to sirukumab to Janssen and discontinue sirukumab development in
giant cell arteritis. - | |||
| NCT03418571 Details | 2019-07-30 Interventional | 2 | 15 | Gontivimab Communicable Di… Infections Respiratory Tra… Respiratory Syn… | The Sponsor decided to discontinue ALX-0171 development (due to insufficient evidence of
efficacy). As a result, the ALX0171-C203 study was early terminated. Based on the results of the Phase IIb study ALX0171-C201 (RESPIRE), the Sponsor decided to discontinue ALX-0171 development in infants and to early terminate the ALX0171-C203 study. Therefore, no data are available for the higher dose groups. | |||
| NCT02769130 Details | 2019-07-30 Interventional | 1/2 | - | Losartan Constriction, P… Stenosis, Pulmo… Children Pulmonary Vein … | Due to Health Canada losartan recall, a new formulation being added to the protocol/ temporary
suspension - | |||
| NCT02707328 Details | 2019-07-30 Interventional | 1 | - | Gemcitabine Paclitaxel Adenocarcinoma Pancreatic Neop… Adenocarcinoma … Pancreas Adenoc… Pancreas Cancer Pancreatic Aden… Pancreatic Canc… | Closed after being on administrative hold - |